Centers | ||
FDA Oncology Center of Excellence Project Catalyst | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | UCSC Chemical Screening Center |
Providing a regulatory platform to connect scientific knowledge, creative insight, and medical professionals to foster early-stage product innovation |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
We are a shared research facility dedicated to improving human health by finding therapeutic agents against a wide variety of diseases, dedicated to advancing scientific knowledge and technologies, and dedicated to education of the next generation of... |
Partnerships |
Events |
Jobs |
Novo Nordisk and Oxford to Develop Drugs to Treat Rheumatoid Arthritis and Other Inflammatory DiseasesNovo Nordisk and Kennedy Institute of Rheumatology at Oxford University have entered into partnership to develop new drugs to treat Rheumatoid Arthritis and other inflammatory disorders. Novo Nordisk will provide research funding support to ten... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Research Collaboration and license agreementThe Drug Discovery Unit announces a partnership with Takeda, Japan’s largest pharmaceutical company, to develop possible new therapeutic treatments for tau pathology, an underlying feature in several forms of neurodegeneration, including... View all |
No EVENTS for listing |
No Job Posts |


